FOLD – Amicus Therapeutics, Inc.
FOLD — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
7.03
Margin Of Safety %
-17
Put/Call OI Ratio
EPS Next Q Diff
-0.08
EPS Last/This Y
EPS This/Next Y
0.75
Price
14.49
Target Price
14.5
Analyst Recom
3
Performance Q
1.47
Upside
N/A
Beta
0.45
Ticker: FOLD
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-23 | FOLD | 14.47 | 0.63 | 0.37 | 10909 |
| 2026-04-24 | FOLD | 14.5 | 0.64 | 0.03 | 11213 |
| 2026-04-27 | FOLD | 14.49 | 0.64 | 0.03 | 11213 |
| 2026-04-28 | FOLD | 14.49 | 0.64 | 0.03 | 11213 |
| 2026-04-29 | FOLD | 14.49 | 0.64 | 0.03 | 11213 |
| 2026-04-30 | FOLD | 14.49 | 0.64 | 0.03 | 11213 |
| 2026-05-01 | FOLD | 14.49 | 0.64 | 0.03 | 11213 |
| 2026-05-04 | FOLD | 14.49 | N/A | N/A | 0 |
| 2026-05-05 | FOLD | 14.49 | N/A | N/A | 0 |
| 2026-05-06 | FOLD | 14.49 | N/A | N/A | 0 |
| 2026-05-07 | FOLD | 14.49 | N/A | N/A | 0 |
| 2026-05-08 | FOLD | 14.49 | N/A | N/A | 0 |
| 2026-05-11 | FOLD | 14.49 | N/A | N/A | 0 |
| 2026-05-12 | FOLD | 14.49 | N/A | N/A | 0 |
| 2026-05-13 | FOLD | 14.49 | N/A | N/A | 0 |
| 2026-05-14 | FOLD | 14.49 | N/A | N/A | 0 |
| 2026-05-15 | FOLD | 14.49 | N/A | N/A | 0 |
| 2026-05-18 | FOLD | 14.49 | N/A | N/A | 0 |
| 2026-05-19 | FOLD | 14.49 | N/A | N/A | 0 |
| 2026-05-20 | FOLD | 14.49 | N/A | N/A | 0 |
| 2026-05-21 | FOLD | 14.49 | N/A | N/A | 0 |
| 2026-05-22 | FOLD | 14.49 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-23 | FOLD | 14.47 | -372.8 | 166.8 | 0.07 |
| 2026-04-24 | FOLD | 14.49 | -372.8 | 167.2 | 0.07 |
| 2026-04-27 | FOLD | 14.49 | -372.8 | 167.2 | 0.07 |
| 2026-04-28 | FOLD | 14.49 | -372.8 | 167.1 | 0.07 |
| 2026-04-30 | FOLD | 14.49 | -372.8 | 167.1 | 0.07 |
| 2026-05-01 | FOLD | 14.49 | -372.8 | 167.1 | 0.07 |
| 2026-05-04 | FOLD | 14.49 | -372.8 | 167.1 | 0.07 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-23 | FOLD | -9.34 | 2.45 | 6.82 |
| 2026-04-24 | FOLD | -9.34 | 2.45 | 6.82 |
| 2026-04-27 | FOLD | -9.34 | 3.65 | 7.09 |
| 2026-04-28 | FOLD | -9.34 | 3.65 | 7.09 |
| 2026-04-29 | FOLD | -9.34 | 3.65 | 7.09 |
| 2026-04-30 | FOLD | -9.34 | 3.65 | 7.09 |
| 2026-05-01 | FOLD | -9.34 | 3.65 | 7.09 |
| 2026-05-04 | FOLD | -9.34 | 3.65 | 7.03 |
| 2026-05-05 | FOLD | -18.77 | 3.65 | 7.03 |
| 2026-05-06 | FOLD | -17.95 | 3.65 | 7.03 |
| 2026-05-07 | FOLD | -17.95 | 3.65 | 7.03 |
| 2026-05-08 | FOLD | -17.95 | 3.65 | 7.03 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.1
Avg. EPS Est. Current Quarter
0.09
Avg. EPS Est. Next Quarter
0.02
Insider Transactions
-17.95
Institutional Transactions
3.65
Beta
0.45
Average Sales Estimate Current Quarter
165
Average Sales Estimate Next Quarter
180
Fair Value
11.98
Quality Score
55
Growth Score
68
Sentiment Score
79
Actual DrawDown %
0.5
Max Drawdown 5-Year %
-61.2
Target Price
14.5
P/E
Forward P/E
17.25
PEG
P/S
7.17
P/B
16.42
P/Free Cash Flow
152.42
EPS
-0.09
Average EPS Est. Cur. Y
0.07
EPS Next Y. (Est.)
0.82
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-4.27
Relative Volume
Return on Equity vs Sector %
-37.2
Return on Equity vs Industry %
-20.4
EPS 1 7Days Diff
-0.6
EPS 1 30Days Diff
-0.57
EBIT Estimation
167.1
No data found for FOLD
Amicus Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 511
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. As of April 27, 2026, Amicus Therapeutics, Inc. operates as a subsidiary of BioMarin Pharmaceutical Inc.
FOLD
Latest News
—
Caricamento notizie per FOLD…
stock quote shares FOLD – Amicus Therapeutics, Inc. Stock Price stock today
news today FOLD – Amicus Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch FOLD – Amicus Therapeutics, Inc. yahoo finance google finance
stock history FOLD – Amicus Therapeutics, Inc. invest stock market
stock prices FOLD premarket after hours
ticker FOLD fair value insiders trading